News from merrimack pharmaceuticals, inc. A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jun 17, 2010, 16:02 ET

Melissa Kemp, Ph.D., Wins the Council for Systems Biology in Boston (CSB2) Award Sponsored by Merrimack Pharmaceuticals, Inc.

Melissa Kemp, Ph.D., was named the winner of the third annual Council for Systems Biology in Boston (CSB2) Award, sponsored by Merrimack...

Jun 03, 2010, 07:00 ET

Merrimack Pharmaceuticals' MM-111 Phase 1/2 Trial Design to be Presented at the 2010 ASCO Annual Meeting

Merrimack Pharmaceuticals, Inc. announced today that the design of their Phase 1/2 trial investigating the safety and tolerability of MM-111 in...

Jun 01, 2010, 16:51 ET

Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference

Merrimack Pharmaceuticals today announced that it will present at the Jefferies 2010 Global Life Sciences Conference in New York City. Robert...

Apr 30, 2010, 14:34 ET

Merrimack to Present at BIO on the Development of MM-111, a Novel Bispecific ErbB2/ErbB3 Antibody with Potent Anti-Tumor Activity

Merrimack Pharmaceuticals' MM-111 Team Leader Charlotte McDonagh, Ph.D., will discuss the development of this novel, bispecific antibody on...

Apr 17, 2010, 07:00 ET

Merrimack to Present Pre-Clinical Data on MM-121 and MM-111 at the 101st Annual Meeting of the American Association for Cancer Research (AACR)

Merrimack Pharmaceuticals, Inc. announced today that it will present pre-clinical data on MM-121 and MM-111, the two lead candidates in the...

Feb 22, 2010, 07:00 ET

Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1/2 Combination Study of MM-121 and Tarceva(R) in Patients with Non-Small Cell Lung Cancer

Merrimack Pharmaceuticals, Inc. announced today that the first patient has received an initial dose in a Phase 1/2 clinical study combining MM-121...

Oct 01, 2009, 07:00 ET

Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody

Merrimack Pharmaceuticals, Inc. and sanofi-aventis announced today the signing of an exclusive worldwide licensing agreement for the...

Sep 21, 2009, 08:05 ET

Merrimack Pharmaceuticals Names Clet Niyikiza, Ph.D. Senior Vice President, Development

Merrimack Pharmaceuticals, Inc., announced today that Clet Niyikiza, Ph.D., has joined the company as Senior Vice President, Development. Dr....

Mar 09, 2009, 09:35 ET

Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development

Merrimack Pharmaceuticals, Inc., a privately held biotechnology company focused on the discovery and development of novel treatments for cancer and...

Aug 11, 2008, 01:00 ET

Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist

CAMBRIDGE, Mass., Aug. 11 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. today announced that the first patient has received an initial dose in...

Jun 10, 2008, 01:00 ET

Merrimack Pharmaceuticals Raises $60 Million in Private Financing

CAMBRIDGE, Mass., June 10 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc., a biotechnology company focused on the discovery and development of...

Mar 14, 2008, 01:00 ET

Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis

CAMBRIDGE, Mass., March 14 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. today announced that enrollment has been completed in a Phase 2 trial...

Nov 29, 2007, 00:00 ET

Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors

CAMBRIDGE, Mass., Nov. 29 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc., a privately held biotechnology company focused on the discovery and...

Jul 23, 2007, 01:00 ET

Merrimack Pharmaceuticals Names William Slichenmyer, M.D. Senior Vice President and Chief Medical Officer

CAMBRIDGE, Mass., July 23 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc., a privately held biotechnology company focused on the discovery and...

Jun 26, 2007, 01:00 ET

Merrimack Pharmaceuticals Names Lisa Evren Senior Vice President and Chief Financial Officer

CAMBRIDGE, Mass., June 26 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc., a privately held biotechnology company focused on the discovery and...

Jun 12, 2007, 01:00 ET

Merrimack Pharmaceuticals Receives U.S. Patent Covering Composition of Matter for Recombinant, Non-Glycosylated Human Alpha-fetoprotein; Extends Patent Protection of Lead Product, MM-093, into 2025

CAMBRIDGE, Mass., June 12 /PRNewswire/ -- Merrimack Pharmaceuticals announced today the issuance of a patent from the United States Patent and...

Apr 17, 2007, 01:00 ET

Merrimack Pharmaceuticals Initiates Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis

CAMBRIDGE, Mass., April 17 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. today announced the initiation of a Phase 2 study to evaluate the...

Apr 04, 2007, 01:00 ET

Merrimack Pharmaceuticals Initiates Enrollment in a Phase 2 Pilot Study of MM-093 in Patients with Autoimmune Uveitis

CAMBRIDGE, Mass., April 4 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. today announced the initiation of a Phase 2 pilot study to determine...

Jul 17, 2006, 01:00 ET

Merrimack Pharmaceuticals Announces the Addition of Louis Weiner, M.D., to its Scientific Advisory Board

CAMBRIDGE, Mass., July 17 /PRNewswire/ -- Merrimack Pharmaceuticals today announced the addition of Louis Weiner, M.D., to its Scientific...

May 15, 2006, 01:00 ET

Merrimack Pharmaceuticals Announces Two Additions to its Board of Directors

CAMBRIDGE, Mass., May 15 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc., a privately held biotechnology company focused on the discovery and...